Search clinical trials for: extended release naltrexone

Total 6571 results

Friends Research Institute, Inc.

Recruiting

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Opioid-use Disorder

United States
Yale University
National Institute on Drug Abuse (NIDA); Baystate Medical Center

Completed

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations (NewHope)

HIV | Opioid Dependence | AIDS | Drug Dependence

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Pharmacotherapy for HIV+ Prisoners (INSPIRE)

Alcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem Drinking

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Alkermes, Inc.

Terminated

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

Alcoholism | Opiate Dependence
Boston University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Disorder hOsPital Treatment Trial (ADOPT)

Alcohol Dependence | Alcohol Use Disorder | Heavy Drinking

United States
NYU Langone Health

Completed

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care (X-ON)

Alcohol Dependence

United States
Drug Delivery Company, LLC DBA Akyso Pharmaceuticals
National Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive...

Not yet recruiting

A Phase 1, Placebo-controlled, Single-Ascending-Dose, Study of BIOPIN 6 in Healthy Adults

Opioid Use Disorder
Duke University
Alkermes, Inc.; Laura and John Arnold Foundation; FHR (Fellowship Health Resources... and other collaborators

Completed

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings (DC)

Opioid-Related Disorders

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Lars Tanum
Oslo University Hospital; Haukeland University Hospital; The Hospital of Vestfold and other collaborators

Completed

Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery (NaltRec)

Opioid-use Disorder

Norway
University of Pennsylvania
Patient-Centered Outcomes Research Institute

Completed

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (OAPXRNTX)

Opiate Dependence

United States
Centre for Addiction and Mental Health

Unknown

Vivitrol Treatment for Cannabis Use Disorder

Cannabis Use Disorder

Canada
Alkermes, Inc.

Completed

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

Alcoholism
Alkermes, Inc.

Completed

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Alcoholism
Alkermes, Inc.

Completed

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

Alcohol Dependence

United States
NYU Langone Health
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Opioid Use Disorder (OUD)

United States
Alkermes, Inc.

Completed

ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

Opiate Dependence

Russian Federation
NYU Langone Health
Alkermes, Inc.

Completed

Extended-release Naltrexone for Alcohol Dependence in Primary Care

Alcohol Dependence

United States
Alkermes, Inc.

Completed

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Alcoholism
Alkermes, Inc.

Completed

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Opiate Dependence

United States
Rhode Island Hospital
National Institute on Drug Abuse (NIDA); Alkermes, Inc.

Completed

Pre-Release VIVITROL for Opioid Dependent Inmates

Substance-Related Disorders

United States
NYU Langone Health
Alkermes, Inc.; New York City Department of Health and Mental Hygiene

Completed

Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

Opiate Dependence

United States
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
University of California, San Francisco
The CARESTAR Foundation

Terminated

Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder

Substance Use | Alcohol Use Disorder | Alcohol Abuse or Dependence

United States
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES)

Opioid Use Disorder | Alcohol Use Disorder

Canada, United States
Alkermes, Inc.

Completed

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

Alcohol Dependence
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
University of California, Los Angeles
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Cocaine Use Reduction With Buprenorphine (CURB)

Cocaine Dependence

United States
NYU Langone Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Alcohol Dependence | Alcohol Use Disorder

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA); Alkermes, Inc.

Completed

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

Alcohol Dependence | Cocaine Dependence

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

HIV | Methamphetamine Abuse

United States
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
University of Oslo
Norwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaborators

Completed

Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)

Opioid Dependence

Norway
Alkermes, Inc.

Completed

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence
NYU Langone Health
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Completed

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (XOR)

Opioid-Related Disorders | Heroin Dependence

United States
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Extended Release Naltrexone for Opioid-Dependent Youth

Drug Dependence

United States
Ensysce Biosciences
PRA Health Sciences

Completed

Study of PF614 Compared to OxyContin® in Healthy Volunteers (SAD)

Healthy

United States
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Pfizer

Completed

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Chronic Noncancer Pain

United States

Search clinical trials for: extended release naltrexone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations